United Therapeutics Corp. (UTHR) announced Monday that the BEAT clinical study of esuberaprost tablets in patients suffering from pulmonary arterial hypertension did not meet its primary endpoint of delayed time to first clinical worsening event.
from RTT - Biotech http://bit.ly/2G7m7kf
via IFTTT
No comments:
Post a Comment